Vistagen Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2014. The filing is an annual report, not a standalone calendar 2013 fourth-quarter filing; it also provides unaudited quarterly results, including the three months ended March 31, 2014.
Business context
Vistagen is a development-stage biotechnology company focused on stem-cell-derived human cell assays for drug safety testing and “drug rescue,” alongside exploratory regenerative medicine research. Its platforms include CardioSafe 3D for cardiac toxicity assessment and LiverSafe 3D, which was still undergoing validation. AV-101, its small-molecule candidate for neuropathic pain and other neurological indications, had completed Phase 1 development. The company had no approved products and no product-sales revenue.
Financial performance and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $0 | $200,400 |
| Research and development expense | $2.481 million | $3.431 million |
| General and administrative expense | $2.548 million | $3.563 million |
| Operating loss | $5.029 million | $6.793 million |
| Net loss | $2.968 million | $12.887 million |
| Operating cash used | $2.126 million | $3.463 million |
- The smaller FY2014 net loss reflected, in significant part, a $3.567 million noncash gain from remeasuring warrant liabilities. FY2013 also included a $3.568 million noncash debt-extinguishment loss and a $10.193 million deemed dividend; net loss attributable to common stockholders was $23.080 million in FY2013 versus $2.968 million in FY2014.
- No revenue was recorded in FY2014 after the NIH grant and subcontract revenue ended. R&D spending fell 28%; management attributed the reduction partly to funding constraints and reduced external research activity. Margins are not meaningful given the absence of revenue.
- Cash and cash equivalents were zero at March 31, 2014, compared with $638,100 a year earlier. Current assets were $40,500 versus current liabilities of $5.206 million. Total assets were $263,700; total liabilities were $13.064 million; stockholders’ deficit was $12.800 million; accumulated deficit was $70.637 million.
- Debt includes senior secured 10% convertible notes and other notes payable; the balance sheet reports current and noncurrent note liabilities, net of discounts, and a $2.974 million warrant liability. The filing describes substantial equity-linked and conversion features, so headline debt balances require review alongside the notes.
- FY2014 financing cash flow was $1.498 million. After year-end, the company reported $1.465 million of cash proceeds from unit placements through June 19, 2014, involving 10% convertible notes, common shares and warrants.
Changes, outlook and risks
- Operating loss narrowed from $6.793 million to $5.029 million, but operations remained loss-making and generated no current-period revenue. The unaudited quarter ended March 31, 2014 had a $1.826 million net loss, compared with $3.770 million in the comparable quarter; warrant-liability remeasurement materially affected quarterly results.
- Management estimated cash expenditures of approximately $4 million to $6 million over the next 12 months and said the company needed $4 million to $6 million in additional financing to execute its plan. It warned financing may not be available on acceptable terms or at all.
- Autilion was contractually committed to invest $36 million for 72 million shares at $0.50 per share, but had completed only a nominal $25,000 closing and was in default. The company gave no assurance of a material closing. A financing above $13 million could give Autilion more than 50% of the common stock and cause a change of control.
- The independent auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern. The statements were prepared on a going-concern basis and contain no adjustments for the outcome of that uncertainty.
- Management said laboratory relocation and limited cash curtailed scientific activity during the year. Priorities included advancing CardioSafe 3D and LiverSafe 3D, evaluating drug-rescue candidates, and seeking strategic partners for AV-101. The filing sets no quantified revenue or earnings guidance.
- Key execution risks include the need for further capital, unproven commercial demand, limited external validation of CardioSafe 3D, incomplete LiverSafe 3D validation, clinical and regulatory uncertainty, reliance on collaborators, and potential dilution. The company also reported significant related-party and equity-linked financing arrangements, including with Platinum and Cato-related entities.
Important facts for investors to verify
- Whether the company secured financing sufficient to cover its stated $4 million to $6 million near-term need, and the terms and dilution from subsequent placements.
- The status and enforceability of the defaulted Autilion agreement and any resulting control or share-issuance consequences.
- Current cash, debt maturities, accrued payables, security interests and conversion or warrant dilution, including Platinum’s Series A exchange rights.
- Independent validation and commercial adoption of CardioSafe 3D, and progress toward full validation of LiverSafe 3D.
- Any AV-101 partnering or clinical-development milestones following Phase 1 completion, and the financing available to advance the program.